HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL

Carson, Robbie; ÇELTİKÇİ, BAŞAK; Fenning, Cathy; Javadi, Arman; Crawford, Nyree; Perez-Carbonell, Lucia; Lawler, Mark; Longley, Daniel; Johnston, Patrick; Van Schaeybroeck, Sandra

doi:10.1158/1078-0432.ccr-14-2701

HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL

Carson R., ÇELTİKÇİ B., Fenning C., Javadi A., Crawford N., Perez-Carbonell L., ...Daha Fazla

CLINICAL CANCER RESEARCH, cilt.21, sa.14, ss.3230-3240, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 21 Sayı: 14
Basım Tarihi: 2015
Doi Numarası: 10.1158/1078-0432.ccr-14-2701
Dergi Adı: CLINICAL CANCER RESEARCH
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.3230-3240
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Hacettepe Üniversitesi Adresli: Hayır

Özet

Purpose: Activating mutations in the BRAF oncogene are found in 8% to 15% of colorectal cancer patients and have been associated with poor survival. In contrast with BRAF-mutant (MT) melanoma, inhibition of the MAPK pathway is ineffective in the majority of BRAFMT colorectal cancer patients. Therefore, identification of novel therapies for BRAFMT colorectal cancer is urgently needed.